For the first time, federal guidelines are aimed at recommending that women between the ages of 30 and 65 get tested for the human papillomavirus (HPV) instead of the traditional cytology (Pap smear).
Women will also be able to opt for a self-administered HPV test; This is a major change by the U.S. Preventive Services Task Force that could affect how millions of women are screened for cervical cancer.
Cervical cancer is one of the most preventable types of cancer; However, recent research indicates that the United States is regressing in its efforts to detect the disease early. The human papillomavirus, which causes virtually all cases of cervical cancer, is the most common sexually transmitted infection.
The recommendation, which is not yet final, came Friday, when panel members voted behind closed doors at the conclusion of a two-day meeting, according to a person familiar with the vote. This person requested anonymity as they were not authorized to make public statements.
The recommendation of this task force—an external body composed mostly of primary care physicians—carries considerable weight. Under the Affordable Care Act, most private insurers are required to cover, at no cost to patients, services recommended by this panel.
A spokesperson for the task force did not respond to a request for comment.
(FDA approves home HPV test to detect cervical cancer)
Under the task force’s previous recommendations, women ages 30 to 65 could choose from three options: a Pap test every three years, an HPV test every five years, or both every five years.
The task force continues to recommend that women between the ages of 21 and 29 have a cytology test every three years.
Sangini Sheth, associate professor of obstetrics, gynecology and reproductive sciences at Yale School of Medicine, said the self-sampling option could improve women’s access to screening.
“Self-sampling is great for people who find it difficult to tolerate a speculum exam, and it expands our ability to offer screening in a variety of settings, such as mobile clinics, free-standing laboratories, or medical specialty offices where pelvic exams are not typically performed,” he said.
Robert Smith, a cancer epidemiologist and senior vice president of science for early cancer detection at the American Cancer Society, said, “Obtaining the sample is a fairly simple process and actually offers accuracy equivalent to that of a sample taken by a doctor.”
For decades, the Pap test — which looks for abnormal or precancerous cells in the cervix — has been the primary method used by doctors to detect cervical cancer. For its part, the HPV test looks for high-risk strains of this virus, which are usually detected before cellular abnormalities appear, allowing women to space more time between one test and another.
(Health experts recommend self-tests to detect uterine cancer)
A 2018 study published in the Journal of the American Medical Association found that HPV tests detect precancerous changes in the cervix earlier and more accurately than the Pap test. The study involved the participation of more than 19,000 women.
Smith explained that some women put off getting a Pap smear because they find it uncomfortable or invasive, especially when performed by a male doctor. Self-testing for HPV—which uses a simple vaginal swab instead of a speculum—is often much more convenient.
“We hope that (the self-test) will increase participation in screening programs,” he added.
According to Sheth, although many women get both tests, most of the benefit comes from the HPV test. The Pap test alone misses a considerable proportion of abnormalities, detecting approximately 50% to 70% of them. Women who skip HPV testing are much more likely to have an HPV-related problem go undetected.
“There is actually no disadvantage to not having the Pap test,” he said.
“It’s superior,” Smith said, referring to the HPV test.
(This Colombian mother with cancer begs for help so that ICE releases her triplets)
Recommendations from working groups are generally considered final when published; however, it is not yet clear when this will occur. It is also unclear whether Health Secretary Robert F. Kennedy Jr. will have to give his approval or seek changes because the Supreme Court last year ruled that he has authority over the panel.
In that case—brought by a Christian-owned company that opposed covering an HIV prevention drug—the court upheld the panel’s authority, arguing that the health secretary can remove its members and review its recommendations.
In September, Kennedy restructured the panel by naming eight new members; Some of them own shares in companies that make drugs and other products affected by the group’s decisions, according to documents consulted by The New York Times. NBC News has not independently verified those documents. Thursday’s meeting was the committee’s first in more than a year.
A spokesperson for the Department of Health and Human Services did not immediately respond to a request for comment.
Smith noted that the task force’s recommendation brings its guidelines closer to those of the American Cancer Society, which began prioritizing HPV testing in 2020.
There are still some differences: The American Cancer Society recommends starting screening at age 25 with HPV testing, while the task force suggests starting at age 21 with Pap testing (cytology) and moving to HPV testing at age 30.
(Blood tests recommended for men for early detection of prostate cancer)
Additionally, for women who collect their own samples, the American Cancer Society recommends testing every three years — not every five — because it wants to have more long-term data before recommending a longer interval, Smith explained.
On Thursday, the task force also clarified which women can stop screening at age 65: only those who have had several consecutive negative results over the past decade. Those who do not meet this criterion should continue to be tested, the group said.
In a statement, a spokesperson for the American College of Obstetricians and Gynecologists said the organization is “closely monitoring the U.S. Preventive Services Task Force’s process to modify cervical cancer screening recommendations, and will evaluate final proposed changes once they are available.”